Taiwan biotechnology, pharmaceutical, medical devices
Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Read moreIn an interview with finance website Deal Street Asia, Singapore-headquartered drug development firm Asian Pharmaceuticals’ CEO Dr Carl Firth discussed why he took the company public in Taiwan and not Singapore, Europe or the US.
Read moreA delegation from the Pharmaceutical Research and Manufacturers of America (PhRMA) made a recent visit to Taiwan and while here urged the government to pass laws that would better strengthen intellectual property protection for pharmaceuticals.
Read more
JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company’s Phase I clinical trial of JHL1101 (a proposed rituximab biosimilar) in rheumatoid arthritis patients.
Read more
After his late wife’s battle with breast cancer, Hon Hai Precision Industry chairman and Taiwan’s richest man Terry Gou started the Yonglin Healthcare Foundation, with the aim of using the best of technology wherever it was developed to take the fight to this disease.
Read moreTo take advantage of its strong science base and a growing number of small innovative companies, Taiwan’s burgeoning biopharmaceutical industry will need to start planning now to develop personnel skilled enough in GMP manufacturing and clinical trials to meet the demands and rigors of such a highly technical field.
Read more
